ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
about
ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.Molecular Demonstration of a Pneumocystis Outbreak in Stem Cell Transplant Patients: Evidence for Transmission in the Daycare Center.Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort.ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.Recommendations for Screening and Management of Late Effects in Patients with Severe Combined Immunodeficiency after Allogenic Hematopoietic Cell Transplantation: A Consensus Statement from the Second Pediatric Blood and Marrow Transplant ConsortiumPulmonary co-infections by Pneumocystis jirovecii and Aspergillus fumigatus in non-HIV patients: A report of two cases and literature review.Infectious complications of rituximab therapy in renal disease.Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.Diagnosis and management of Pneumocystis jirovecii infection.The use of intravenous pentamidine for the prophylaxis of Pneumocystis pneumonia in pediatric patients.Severe pneumocystis jiroveci pneumonia in a patient on temozolomide therapy: A case report and review of literature.Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies.Influenza and Pneumocystis jirovecii pneumonia in an allogeneic hematopoietic stem cell transplantation recipient: Coinfection or superinfection?Fatal infection of Pneumocystis jiroveci pneumonia in a pemphigus patient treated with rituximab.Pneumocystis jirovecii pneumonia in patients with acute myeloid leukaemia.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphatInfectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant.Intravenous pentamidine for Pneumocystis pneumonia prophylaxis in children undergoing autologous hematopoietic stem cell transplant.Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii.Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients.Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients.
P2860
Q30248345-B751FFA2-55BF-45C0-BF1D-F2F42F999D16Q33593287-69A4640A-95D7-4F9C-9EFA-90A6BE7C14FFQ38902083-73D7C001-4795-4E9F-95F9-3C93F31EA668Q38934528-A50B326F-63D6-4EF4-8B87-E01C70CF0A8BQ38953280-15BE8E28-31D0-4FDA-95DC-1EB7D949CF1DQ39264020-0333364E-B658-4CC8-9600-BB976859266AQ39289010-92671CC9-B7A8-400E-A37C-EEEE2A176CD5Q39404140-5B3A44F6-F907-4FF2-84DC-7F3B4DD68772Q40065728-1C2FA35F-75AE-4397-B8DE-89DBD6FA0F49Q40092648-2133A1C5-11CF-4CD4-A261-98462A567956Q40297079-51909A74-15E5-4A18-B1A4-37AAE95A485EQ40377054-854E90DF-0983-41CD-9C75-2C683A1BC357Q41502821-15C80237-5A55-4A45-934D-0BEB18778F2EQ47205373-6B2C0EB7-207D-4BE8-8198-502C107BCF51Q47665239-1407991B-301E-4E05-AB81-D4AB9C60756CQ47983751-7929DC45-2C6A-41ED-A350-96E65B15F0B3Q48286433-B655BD6D-DA62-4FF6-9B90-3AE08335DB21Q50086043-99211348-8292-4F1B-8034-0589C23E8F37Q52728829-A21440C8-6651-4CB7-B154-542708EE0193Q52738699-7135E328-655C-42BD-8CD5-B02DE990A26AQ53839475-9DF06695-AE87-40FD-9243-9CA6AD151BE5Q54432895-50000E17-0FBF-4B15-BCA3-7137225E58D8Q54534916-863097D1-611C-4099-A27E-8E4543692C05Q55545384-8C1A549B-6A24-4850-A232-6AE0D48F5C7D
P2860
ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
ECIL guidelines for preventing ...... em cell transplant recipients.
@en
type
label
ECIL guidelines for preventing ...... em cell transplant recipients.
@en
prefLabel
ECIL guidelines for preventing ...... em cell transplant recipients.
@en
P2093
P2860
P50
P356
P1476
ECIL guidelines for preventing ...... em cell transplant recipients.
@en
P2093
5th European Conference on Inf ...... the European LeukemiaNet (ELN)
Alexandre Alanio
Catherine Cordonnier
Georg Maschmeyer
J Peter Donnelly
Jannik Helweg-Larsen
Johan Maertens
Katrien Lagrou
Stéphane Bretagne
Willem J G Melchers
P2860
P304
P356
10.1093/JAC/DKW157
P407
P577
2016-05-12T00:00:00Z